Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics

(2009) Wilko Weichert et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

BRAFMutation in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

(2009) Jens Neumann et al.   PATHOLOGY RESEARCH AND PRACTICE

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

(2008) F Di Fiore et al.   BRITISH JOURNAL OF CANCER

Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer

(2008) Salvatore Artale et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

(2008) J. H. J. M. van Krieken et al.   VIRCHOWS ARCHIV